Abstract
Until recently, FK 506 was used only for rescue therapy after pancreas transplantation. We report our initial experience with FK 506 for 67 pancreas recipients (treated between 1 May 1993 and 30 April 1995). Of these recipients, 49 (73%) received FK506 for induction and maintenance therapy, 12 (18%) for rescue or antirejection therapy, and 6 (9%) for reasons other than rescue or antirejection therapy. In our induction and maintenance therapy group, 32 recipients (65%) underwent a simultaneous pancreas-kidney transplant (SPK), 8 (16%) a pancreas transplant alone (PTA), and 9 (19%) a pancreas after previous kidney transplant (PAK). Quadruple immunosuppression was used for induction; the median FK506 starting dose was 4 mg/day p. o. and target levels were 10–20 ng/ ml. The most common side effects were nephrotoxicity (16%) and neurotoxicity (14%); transient episodes of hyperglycemia were also noted (12%), in particular in the presence of concurrent rejection and infection episodes. A matched-pair analysis was done to compare graft outcome with FK 506 versus cyclosporin A (CsA). For SPK recipients, pancreas graft survival at 6 months was 79% with FK 506 versus 65% with CsA (P = 0.04), for PTA, 100% versus 63% (P > 0.35), and for PAK, 88% versus 33% (P > 0.01). Pancreas graft loss due to rejection at 6 months posttransplant was lower with FK506 versus CsA. Two FK 506 recipients died from B-cell lymphomas (Epstein-Barr virus positive) at 6 and 7 months post-transplant. In our rescue or anti-rejection group, 5 recipients underwent SPK, 3 PTA, and 4 PAK. The mean average FK 506 dose was 10 mg/day p. o. and the mean average FK506 blood level was 11 ng/ml. The most common side effects were nephrotoxicity (33%) and neurotoxicity (16%). Two recipients developed hyperglycemic episodes, of whom 1 has remained on insulin with good exocrine pancreas graft function. Graft survival at 6 months after conversion was 75% for SPK, 67% for PTA, and 50% for PAK. Only one graft was lost due to chronic rejection. Our single-center experience shows that FK 506 after pancreas transplantation is associated with: (1) a low rate of graft loss due to rejection when used for induction, in particular for solitary pancreas transplants, (2) a high rate of graft salvage when used for rescue, (3) a 1% rate of new-onset insulin-dependent diabetes mellitus, and (4) a 3% rate of posttransplant lymphoma. Further studies are necessary to analyze the long-term impact of FK506 on pancreas transplant outcome.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cox KL, Lawrence-Miyaskai LS, Garcia-Kennedy R, et al (1995) An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 59: 425
Gruessner RWG, Sutherland DER (1996) Clinical diagnosis in pancreatic allograft rejection. In: Solez K, Racusen LC, Billingham M, Dekker M (eds) Pathology and rejection diagnosis in solid organ transplantation. New York, pp 455–499
Hirano Y, Fujihara S, Ohara K, Katsuki S, Noguchi H (1992) Morphological and functional changes of islets of Langerhans in FK506-treated rats. Transplantation 53: 889
Kaufman DC, Kaplan B, Kanwar Y, Abecassis M, Stuart F (1995) The successful use of tacrolimus (FK 506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome. Transplantation 59: 1737–1739
Klintmalm G (1994) The U. S. Multi-center FK 506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression after liver transplantation. N Engl J Med 331: 1110
Reyes J, Tzakis AG, Bonet H, et al (1994) Lymphoproliferative disease after intestinal transplantation under primary FK 506 immunosuppression. Transplant Proc 26: 1426
Shaffer D, Simpson MA, Conway P, Madras PN, Monaco AP (1995) Normal pancreas allograft function following simultaneous pancreas kidney transplantation after rescue therapy with tacrolimus (FK506). Transplantation 59: 1063
Shapiro R, Jordan ML, Scantlebury VP, et al (1995) A prospective randomized trial of FK 506-based immunosuppression after renal transplantation. Transplantation 59: 485
Teraoka S, Babazono T, Koike T, et al (1995) Effect of rescue therapy using FK506 on relapsing rejection after combined pancreas and kidney transplantation. Transplant Proc 27: 1335
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Gruessner, R.W.G., Sutherland, D.E.R., Drangstveit, M.B., Troppmann, C., Gruessner, A.C. (1996). Use of FK 506 in pancreas transplantation. In: Mühlbacher, F., et al. Transplant International . Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-00818-8_65
Download citation
DOI: https://doi.org/10.1007/978-3-662-00818-8_65
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-61024-3
Online ISBN: 978-3-662-00818-8
eBook Packages: Springer Book Archive